Online inquiry

IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7126MR)

This product GTTS-WQ7126MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets LHCGR gene. The antibody can be applied in Controlled Ovarian Stimulation (COS) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000233.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3973
UniProt ID P22888
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ7126MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14408MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ4343MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BIW-8405
GTTS-WQ13308MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-06741086
GTTS-WQ13264MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-06252616
GTTS-WQ12995MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PEG-G-CSF
GTTS-WQ7049MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ14431MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ2510MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 334
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW